Regeneron Partnering With Ocular May Provide Needed Tech Validation

Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.

Beset with clinical trial disappointments in the past year, Ocular Therapeutix Inc. obtained a much-needed validation of its technology Oct. 13 as it announced a collaboration with Regeneron Pharmaceuticals Inc. to develop a sustained-release version of Eylea (aflibercept) with a goal of producing a formulation that will only need to be dosed two or three times a year, rather than every other month.

Currently in preclinical development, the candidate will employ Ocular's proprietary sustained-release hydrogel-based drug delivery depot formulation for intravitreal injection. In...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from Scrip

Rocket Comes Back To Earth With Restructuring Plan

 

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.